Indoco Remedies receives USFDA approval for Rivaroxaban Tablets
Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg and 20 mg are bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xarelto Tablets, 2.5 mg, 10 mg, 15 mg and 20 mg, of Janssen Pharmaceuticals, Inc. (Janssen).
Rivaroxaban Tablets USP, will be manufactured by Indoco Remedies Limited, at their manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa 403722 in India.
Rivaroxaban is used for the treatment of venous thromboembolism (VTE).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
a day ago
- Business Standard
Alembic Pharmaceuticals receives USFDA approval for Tretinoin Cream USP
Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Tretinoin Cream USP, 0.025%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Retin-A Cream, 0.025%, of Bausch Health US, LLC. Tretinoin cream is indicated for topical application in the treatment of acne vulgaris. Tretinoin cream USP, 0.025%, has an estimated market size of US$ 94 million for twelve months ending June 2025 according to IQVIA.
Business Standard
a day ago
- Business Standard
Alembic Pharma secures USFDA nod for generic acne cream
Alembic Pharmaceuticals said on Friday it has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Tretinoin Cream USP, 0.025%. The product is therapeutically equivalent to Bausch Health's Retin-A Cream, 0.025%, and is indicated for the topical treatment of acne vulgaris. The cream has an estimated market size of $94 million for the 12 months ended June 2025, according to IQVIA. With this nod, Alembics cumulative ANDA approvals now stand at 224, including 202 final and 22 tentative approvals. Alembic Pharmaceuticals is a vertically integrated research-driven company that manufactures and markets generic medicines globally. The company's consolidated net profit jumped 14.18% to Rs 156.63 crore while revenue from operations grew 9.54% to Rs 1,710.72 crore in Q1 June 2025 over Q1 June 2024.
Fibre2Fashion
3 days ago
- Fibre2Fashion
US' Coach drives Tapestry's FY25 gains, Kate Spade declines
American fashion holding company Tapestry, Inc, owner of Coach, Kate Spade, and Stuart Weitzman, has reported fiscal 2025 (FY25) revenue of $7.01 billion, up 5 per cent from the prior year on both reported and constant currency bases, with double-digit growth in Europe (+28 per cent) and Greater China (+5 per cent), and 10 per cent constant currency growth at Coach. Revenues in the fourth quarter (Q4), ended June 28, rose 8 per cent to $1.72 billion, with gains across North America (+8 per cent), Europe (+10 per cent), and APAC (+6 per cent). Gross margin expanded 210 basis points for the year and 140 basis points in Q4, driven by operational efficiencies. Coach delivered $5.6 billion in annual revenue (+10 per cent constant currency), while Kate Spade fell 10 per cent to $1.20 billion and Stuart Weitzman dropped 11 per cent to $215 million. Kate Spade recorded $855 million in impairment charges due to reduced cash flow expectations and anticipated tariff impacts, the company said in a media release. Tapestry, Inc has posted FY25 revenue of $7.01 billion, up 5 per cent, led by growth at Coach and in Europe and Greater China. Q4 sales rose 8 per cent, with gross margin gains. The company returned $2.3 billion to shareholders and will raise its dividend 14 per cent in FY26. EPS is seen at $5.30â€'$5.45, despite a $160 million tariff hit. Adjusted free cash flow is forecast at $1.3 billion. The company added 6.8 million new customers during the year—60 per cent from Gen Z and Millennials—while direct-to-consumer revenue grew 5 per cent annually, supported by mid-teens digital sales growth. Handbag sales at Coach saw mid-teens average unit retail (AUR) gains in Q4 and low double-digit gains for the year. On a non-GAAP basis, FY25 operating income reached $1.40 billion (20 per cent margin) versus $1.25 billion last year, and EPS rose to $5.10 from $4.29. GAAP net income was $183 million ($0.82 EPS), down from $816 million, reflecting impairment, organisational efficiency, and transaction-related charges. Adjusted free cash flow was $1.35 billion. Tapestry returned $2.3 billion to shareholders in FY25—$300 million in dividends and $2 billion through an accelerated share repurchase (ASR) programme at an expected $78 average price. For FY26, the board has approved a 14 per cent dividend increase to $1.60 per share annually and authorised $800 million in additional buybacks. Joanne Crevoiserat, chief executive officer of Tapestry, Inc , commented: 'Fiscal 2025 was a breakout year for Tapestry as our systemic approach to brand-building is capturing a new generation of consumers around the world. Our strong growth, capped by our fourth quarter outperformance, reinforces that our strategies are working. Importantly, we achieved bold targets we set three years ago in a dynamic landscape, delivering over $5 in adjusted earnings per share and returning more than $3 billion cumulatively to shareholders. Looking ahead, the creativity, craftsmanship, and compelling value we offer at scale—combined with the agility of our operating model—position us to drive compounding long-term growth and shareholder value.' For FY26, Tapestry forecasts revenue approaching $7.2 billion, with mid-single-digit pro-forma growth excluding Stuart Weitzman, and EPS of $5.30–$5.45, despite a projected $160 million hit from incremental tariffs and duties (230 basis points of margin impact). Adjusted free cash flow is expected at about $1.3 billion. Fibre2Fashion News Desk (KD)
